Annette Clancy
Vorsitzender bei SWEDISH ORPHAN BIOVITRUM AB
Vermögen: 93 613 $ am 30.04.2024
Aktive Positionen von Annette Clancy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Independent Dir/Board Member | 08.05.2014 | - |
Vorsitzender | 05.01.2024 | - | |
Direktor/Vorstandsmitglied | 08.05.2014 | 05.01.2024 | |
Abcd Ltd. | Direktor/Vorstandsmitglied | - | - |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Vorsitzender | - | - |
Independent Dir/Board Member | - | - |
Karriereverlauf von Annette Clancy
Ehemalige bekannte Positionen von Annette Clancy
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OBSEVA SA | Direktor/Vorstandsmitglied | 01.12.2016 | 18.05.2022 |
Vorsitzender | 18.05.2022 | 10.03.2023 | |
Independent Dir/Board Member | 01.11.2013 | 10.03.2023 | |
LYSOGENE | Direktor/Vorstandsmitglied | 22.05.2019 | 26.09.2019 |
Vorsitzender | 14.04.2015 | 22.05.2019 | |
Independent Dir/Board Member | 22.05.2019 | 26.09.2019 | |
WEIFA ASA | Direktor/Vorstandsmitglied | 20.05.2010 | 21.05.2013 |
SILENCE THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 01.07.2008 | 02.08.2012 |
GSK PLC | Corporate Officer/Principal | 01.01.1978 | 01.01.2008 |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Vorsitzender | - | - |
Ausbildung von Annette Clancy
University of Bath | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 5 |
Frankreich | 3 |
Norwegen | 2 |
Operativ
Director/Board Member | 6 |
Chairman | 5 |
Independent Dir/Board Member | 4 |
Sektoral
Health Technology | 7 |
Commercial Services | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
GSK PLC | Health Technology |
SILENCE THERAPEUTICS PLC | Commercial Services |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
OBSEVA SA | Health Technology |
LYSOGENE | Commercial Services |
Private Unternehmen | 4 |
---|---|
Weifa ASA
Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Health Technology |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Health Technology |
Abcd Ltd. |
- Börse
- Insiders
- Annette Clancy
- Erfahrung